Background
==========

Expression of a variant surface antigen is utilised by a wide variety of pathogenic micro-organisms to evade the immune defences of the host, thereby prolonging the duration of infection and increasing the likelihood of transmission. In the early part of the last century microbiologists first observed this process in relapsing fever caused by Borreliae as the spirochaetes recovered from each relapse differed serologically. The classical molecular description of this phenomenon comes from studies of *Borrelia hermsii*, an aetiologic agent of tick-borne relapsing fever. Variable major proteins are the dominant surface antigen \[[@B1]\], which are involved in evasion of the host\'s immune system as Borreliae emerging at each relapse express a different antigenic form \[[@B2]\]. Detailed molecular analysis has revealed that the corresponding genes are arranged into silent and expressed copies on different plasmids \[[@B3],[@B4]\]. Antigenic variation occurs by replacement of the entire open reading frame of the expressed gene by a previously silent one, or by activation of a previously silent downstream gene \[[@B3]-[@B8]\]. Recently the variant major proteins, formerly denoted Vmp, have been divided into two groups based on size, namely the variant large proteins (encoded by *vlp* genes of typical size 1 kbp) and variant small proteins (encoded by *vsp* genes of typical size 0.6 kbp).

The present study considers the related organism *B. recurrentis*, the causative agent of louse-borne relapsing fever (LBRF). LBRF is a systemic inflammatory disease, which, if untreated, is associated with mortality rates of up to 40% \[[@B9]\]. This is reduced to 2--4% by use of antibiotics. Although the disease is relatively localised at present, with an endemic focus in Ethiopia, the potential for epidemics remains. Indeed the most recent outbreak occurred in the Sudan \[[@B10]\]. The disease is characterised by high fevers due to production of inflammatory mediators by the host in response to spirochaetal toxins \[[@B11],[@B12]\]. It has been shown that the major pro-inflammatory molecule of *B. recurrentis* clinical isolate A1 is highly homologous to Vlp12~*B.\ hermsii\ HS1*~, and is here referred to as Vlp1~*B.\ recurrentis\ A1*~\[[@B13]\].

Studies of the molecular biology of *B. recurrentis* have been hampered by the lack of an animal model. The first cultivation of a clinical isolate *in vitro* was achieved in 1993 \[[@B14]\] and to date eighteen clinical isolates have been characterised by their plasmid profile and by the expression of a putative Vlp or Vsp \[[@B15]\]. As the first step to study antigenic variation in *B. recurrentis*, we report the complete organisation and characterisation of *vlp1*~*B.\ recurrentis\ A1*~ gene coding for the variant surface antigen of this isolate.

Methods
=======

*Borrelia recurrentis* isolates
-------------------------------

Isolates A1 and A17 from Ethiopian patients with LBRF and were subcultured *in vitro* as previously described \[[@B14],[@B15]\]. There was no change in protein profiles or plasmid DNA banding patterns during this investigation compared with those observed for each isolate following original isolation from patients described previously \[[@B14],[@B15]\].

Nucleic acid purification
-------------------------

Plasmid and chromosome-rich DNA fractions were prepared as described \[[@B30]\]. Total RNA was purified using the TRI Reagent method \[[@B31]\] (Sigma) and resuspended in RNase-free water.

Probe labelling
---------------

The 715 bp PCR product amplified from part of the expressed *vlp1*~*B.\ recurrentis\ A1*~ gene \[[@B13]\] was labelled with a^32^P-dCTP by random-priming (Amersham-Pharmacia Biotech). Oligonucleotide probes (LLS1, CACCA CTATCATCATCATCAAT and LLS2, TCATCACCATCACCAGCACC) were labelled with ?^32^P-ATP by enzymatic phosphorylation with polynucleotide kinase (Roche Molecular Biochemicals; the sequences corresponding to the probes LLS1 and LLS2 are double-underlined in Fig. [2](#F2){ref-type="fig"}). All radioactive probes were purified (Chromaspin-10, Clontech) prior to hybridisation.

![**vlp1~*B.\ recurrentis\ A1*~ is plasmid encoded and duplicated in isolate A1.** A: Plasmid (lane 1 to 4) and chromosome-rich (lane 5 to 8) DNA were digested with EcoRI (lane 1 and 5), HindIII (lane 2 and 6), XbaI (lane 3 and 7), and DraI (lane 4 and 8), transferred to a membrane and hybridised under high stringency with the 715 bp *vlp1* probe. B: Plasmid DNA from isolate A1 (lane 1 to 3) and isolate A17 (lanes 4 to 6) and total DNA from isolate A17 (lane 7) were digested with HindIII (lane 1 and 4), EcoRI (lane 2, 5, and 7), XbaI (lane 3 and 6), and treated as described above. C: Intact plasmids from isolate A1 (lane 1) and isolate A17 (lane 2) were separated by field inversion gel electrophoresis (predefined program P1, Biorad) and treated as described above.](1471-2334-2-25-1){#F1}

![**Ungapped DNA sequence alignment of the two forms of vlp1~*B.\ recurrentis\ A1*~** The upper row represents the sequence derived from the slower migrating 54 kbp plasmid of figure [1C](#F1){ref-type="fig"}. The sequence corresponding to the UP element consensus found in the bottom row sequence is italicised. The putative \'-35\' and \'-10\' elements and ribosome binding sites are underlined. Translation start sites are shown in bold. Region complementary to LLS1 and LLS2 probes are double-underlined. Accession number for both sequences are given in the methods section.](1471-2334-2-25-2){#F2}

Library construction and screening
----------------------------------

Plasmid DNA from isolate A1 was digested to completion with HindIII. Fragments of relevant sizes were gel purified using QIAEXII kit (Qiagen) and ligated in pBluescript linearised with HindIII. A portion of the ligation reaction was used to transform library efficient *E. coli* DH5a strain (GIBCO-BRL). Colonies were lifted onto Hybond-N membranes (Amersham-Pharmacia Biotech) and hybridised at high stringency with the 715 bp *vlp1* probe as described \[[@B32]\]. After a second round of screening, positive clones were sequenced on an ABI377 automated sequencer using BigDye Terminator (Applied Biosystem). Sequences were assembled and analysed using the Wisconsin Genetics Computer Group, Madison, WI software package.

Southern hybridisation
----------------------

Eight hundred nanograms of DNA were digested with a range of restriction enzymes. Digestion products were fractionated on a 1% agarose TAE gel. After electrophoresis the gel was treated as described \[[@B32]\] prior to capillary transfer onto Hybond-N membranes (Amersham-Pharmacia Biotech) in 10 × SSC overnight. Following UV-crosslinking, blots were hybridised in Rapid-Hyb solution (Amersham-Pharmacia Biotech) and washed using high stringency conditions (0.5 × SSC/0.1% SDS and 0.1 × SSC/0.1% SDS at 65°C each for 15 minutes).

Field inversion gel electrophoresis
-----------------------------------

One microgram of plasmid DNA from isolates A1 or A17 were separated by field inversion gel electrophoresis on a 1% agarose, 0.5 × TBE gel using the predefined programme P1 to separate DNA fragments between 150 kbp and 5 kbp (Biorad).

Northern hybridisation
----------------------

One and a half microgram of total RNA were separated on a formaldehyde agarose gel and transferred onto a Hybond-N membrane in 10 × SSC. Following UV-crosslinking, blots were hybridised in Rapid-Hyb solution (Amersham-Pharmacia Biotech) and washed using high stringency. When labelled oligonucleotides were used as probes, hybridisations were carried out at 1°C below the calculated melting temperature.

Database accession numbers
--------------------------

Expressed *vlp1*~*B.\ recurrentis\ A1*~: AJ237608; Silent *vlp1*~*B.\ recurrentis\ A1*~: AJ237609.

Results
=======

vlp1~*B.\ recurrentis\ A1*~ is plasmid encoded
----------------------------------------------

A probe encoding a 715 bp portion of the expressed *vlp1*~*B.\ recurrentis\ A1*~, generated by microsequencing \[[@B13]\] was used to characterise *vlp1* in two distinct *B. recurrentis* isolates. Plasmids and chromosome-rich extracts from isolate A1 were digested with several restriction endonucleases. This was followed by Southern hybridisation with the 715 bp *vlp1* probe. Restriction enzymes that do not cleave the region of DNA encompassing the hybridisation probe were used.

As shown in figure [1A](#F1){ref-type="fig"}, two bands were detected in the plasmid extract under high stringency hybridisation conditions. A third band of 43 kbp was observed at lower stringency conditions (data not shown). In contrast, the chromosomal-rich extract gave only weak hybridisation signals, probably caused by contaminating plasmid DNA. When the same experiment was performed on total and plasmid DNA from isolate A17 under high stringency, only one band could be detected (fig. [1B](#F1){ref-type="fig"}; lane 4 to 7).

To confirm these findings, plasmids from both isolates were separated using field inversion gel electrophoresis (FIGE). Ethidium bromide staining revealed six major plasmid species in the range of 10 to over 100 kbp (not shown). Hybridisation under high stringency with the *vlp1* probe detected a common band between isolate A1 and A17 corresponding to a plasmid of about 54 kbp (fig. [1C](#F1){ref-type="fig"}). This was also detected by the *vlp1* probe in 10 further isolates possessing the 54 kbp plasmid. However, an extra band was detected in isolate A1 corresponding to a plasmid of about 24 kbp. Similarly, this 24 kbp band was also present in three other isolates falling into the same group of *B. recurrentis*\[[@B15]\]. Densitometry analysis showed that the signal intensity of the 24 kbp plasmid was about 3 to 4 times higher than the intensity given by the 54 kbp plasmid. These results show that *vlp1*~*B.\ recurrentis*~ is plasmid-encoded and in isolate A1 the two *vlp1* loci are localised on different plasmids. These results also raise the possibility that silent and expressed copies of *vlp1* are present in *B. recurrentis* A1, whereas isolate A17 possesses only the silent copy.

Sequence of the vlp1~*B.\ recurrentis\ A1*~ loci
------------------------------------------------

To investigate further the *vlp1*~*B.\ recurrentis*~ loci we screened a partial library of isolate A1 plasmid DNA with the *vlp1* probe. Positive clones of two different sizes were obtained, corresponding to the*vlp1* loci carried on the 54 and 24 kbp plasmids depicted in figure [1C](#F1){ref-type="fig"}. The ungapped alignment of the two copies of *vlp1*~*B.\ recurrentis\ A1*~ is presented in figure [2](#F2){ref-type="fig"}; sequence 1 is derived from the slower migrating 54 kbp plasmid. Overall these two sequences are about 65% A/T rich in keeping with the low G/C content of borrelial DNA \[[@B16]\]. There is an extensive region (1461 bp) of strict identity that starts in the *vlp1*~*B.\ recurrentis*~ open reading frame and extends beyond the stop codon. An additional feature of this region is the presence downstream of the open reading frame starting at nt1385 of a 300 bp segment that possesses 73% identity with the *vlp1*~*B.\ recurrentis\ A1*~ gene itself. Analysis of the translated sequences showed that the N-terminal component is not conserved, the identity between the two sequences starts one residue before the unique cysteine. Both N-terminal sequences code for a putative lipoprotein leader signal sequence \[[@B17],[@B18]\], consistent with the finding that Vlp1~*B.\ recurrentis\ A1*~ has a lipid modification \[[@B13]\]. The divergence in the 5\' end of the *vlp1* coding region extends upstream where the two sequences are highly dissimilar. Interestingly, the upstream region of sequence 2 is richer in pyrimidine than that of sequence 1 (pyrimidine content of 59% and 34% respectively). However, both upstream regions possess a potential ribosome binding site and imperfect -10 and -35 regions, the consensus recognition site for s 70 RNA polymerase. In addition sequence 2 has a nearly perfect consensus UP element \[[@B19]\], the binding site for the C-terminal domain of the RNA polymerase, and an unusually long uninterrupted tract of 42 dT. Of note, another potential translational start is found in sequence 2 at nucleotide 191, with the -10 region starting at position 141 (not shown).

Taken together these results show that the two *vlp1*~*B.\ recurrentis\ A1*~ genes code for the same mature protein but have a different lipoprotein leader sequence. In addition, the presence of putative promoter features in upstream regions of both genes leaves the question of silent and expressed copies unresolved.

vlp1~*B.\ recurrentis*~ is organised into silent and expressed copies
---------------------------------------------------------------------

The total RNA were extracted from isolates A1 and A17 respectively, and Northern hybridisation was performed using oligonucleotide probes specific for the two lipoprotein leader signal sequences (LLS1 & LLS2), and the partial *vlp1* probe. When the *vlp1* probe was used, a strong hybridisation signal corresponding to a mRNA of around 1.2 kb was obtained only from isolate A1 (Fig. [3](#F3){ref-type="fig"}). This illustrates that *vlp1*~*B.\ recurrentis\ A1*~ is expressed only in isolate A1, but not in A17. No signal was detected when the oligonucleotide probe LLS1 specific for leader sequence 1 was used. In contrast, the LLS 2 specific probe detected a 1.2 kb RNA corresponding to *vlp1*~*B.\ recurrentis\ A1*~ message only in RNA extracted from isolate A1. Of note, probe LLS2 detected a message of about 800 b only in isolate A17 RNA. These results demonstrate that there is a silent and expressed copy of *vlp1* in *B. recurrentis* A1; sequence 2 in figure [2](#F2){ref-type="fig"} representing the expressed copy of *vlp1*~*B.\ recurrentis\ A1*~.

![**vlp1~*B.\ recurrentis\ A1*~ is organised into silent and expressed copies.** Total RNA from isolates A1 and A17 were separated on an agarose gel, blotted to a membrane and hybridised with specific probes. A: 715 bp *vlp1*; B: LLS1-specific probe; C: LLS2-specific probe](1471-2334-2-25-3){#F3}

Discussion
==========

The dominant surface antigen of *Borrelia* is a variant protein encoded by a large repertoire of genes, only one of which is expressed at anyone time. In contrast to other borreliae, the study of antigenic variation in *B. recurrentis* has been hampered by the lack of an animal model of infection. Isolates can only be recovered from patients and further characterised in vitro. Nevertheless, as the first step to better understand this phenomenon, we report the first complete characterisation of *vlp1*~*B.\ recurrentis\ A1*~ gene from a clinical isolate. This gene has common features with variant protein genes from other *Borrelia* species but has some intriguing features.

In isolate A1, which expresses the Vlp1~*B.\ recurrentis\ A1*~ protein \[[@B13],[@B15]\], there are two copies of *vlp1*~*B.\ recurrentis\ A1*~, one on a 54 kbp plasmid and the other on a 24 kbp plasmid. This is reinforced by the observation of hybridisation with these two plasmids and the 715 bp *vlp*1 probe in other A1 group members (isolates A2--A4) \[[@B15]\]. The third plasmid, which hybridised at lower stringency, may carry an A1-like, but different *vlp* gene. In isolate A17, which expresses a different form of variant protein, *vlp1*~*B.\ recurrentis\ A17*~ is found only on the 54 kbp plasmid. Sequence analysis shows that absolute identity between the two *vlp1* copies in isolate A1 starts 5 nucleotides upstream of the unique cysteine codon. This cysteine is the N-terminal amino acid of the mature Vlp1~*B.\ recurrentis*~ and is the attachment point for the lipid modification of the variant protein \[[@B17],[@B20]\]. Upstream of this region the two copies are divergent but both sequences fit the lipoprotein leader consensus sequence. Using oligonucleotides probes specific for these two leader sequences we demonstrate by Northern analysis that only the *vlp1*~*B.\ recurrentis\ A1*~ copy present on the 24 kbp plasmid is expressed in isolate A1. This result suggests that silent *vlp1*~*B.\ recurrentis\ A1*~, carried on a 54 kbp plasmid, may have undergone a duplicative translocation to the active expression site on a 24 kbp plasmid. Of note, 12 the 18 *B. recurrentis* clinical isolates described to date, one of which is isolate A17, possess a plasmid migrating in the region of 24 to 31 kbp \[[@B15]\].

This organisation is similar to that of other relapsing fever borreliae in which expressed and archived variant protein genes are located on different plasmids \[[@B6],[@B21],[@B22]\]. In these borreliae, the use of an animal model of infection has allowed the precise delineation of events taking place during an antigenic switch. In *B. hermsii*, antigenic variation occurs by replacement of one variable gene with another downstream from a telomeric promoter. In *B. turicatae*, gene conversion is more extensive, involving 10 or more kilobases downstream of the promoter giving rise to changes in the size of the plasmid carrying the expression site \[[@B22]\]. However, a third of *B. recurrentis* clinical isolates do not possess a plasmid migrating in the 24 kbp region \[[@B15]\]. Hence, it is possible that this plasmid was lost during in vitro cultivation or alternatively, as these isolates express a major antigen \[[@B15]\], there may exist an expression site located on a different plasmid. Indeed, activation of an alternative expression site has already been described in *B. hermsii*\[[@B23]\], utilised for expression of the vector transmission associated protein Vtp33 \[[@B24]\].

Based on the sequence alignment between silent and expressed *vlp1*~*B.\ recurrentis\ A1*~, it is tempting to speculate that the recombination site having given rise to expressed *vlp1* is located where the two sequences become identical; that is within the open reading frame itself. Such a model would be supported by the finding that the probe specific for the lipoprotein leader sequence of the expressed *vlp1*~*B.\ recurrentis*~ recognises a message of around 800 bases in RNA purified from isolate A17. The size of this message is in agreement with the theoretical size of the major antigen, Vsp17~*B.\ recurrentis\ A17*~, expressed by isolate A17 as determined previously by protein gel electrophoresis \[[@B15]\]. Further analysis of sequences from other variant protein genes should answer this point.

It is not clear how a rapid and successful antigenic switch is achieved in either *B. recurrentis* or *B. hermsii*\[[@B25]\] since for both species there is an approximately threefold excess of the expression plasmid compared to the silent plasmid. Clearly, maintenance and copy number for the two plasmids are differentially controlled and this may provide an opportunity to specifically modulate the copy number of the silent plasmid prior to a switching event.

The upstream region of both expressed and silent *vlp1*~*B.\ recurrentis\ A1*~ possesses potential promoter sequence, whose way of functioning remains speculative. Firstly, the expressed *vlp1* contains an unusually long polydT tract that starts 167 nucleotides from the putative initiating codon. Shorter polydT tracts closer to the initiating codon (adjacent to the -35 region of the promoter) of two lipoprotein genes of other *Borrelia* species have been shown to have a role in transcriptional regulation \[[@B26]\]. It may be that this region replaces the UP element since such a consensus sequence could not be found in these promoters \[[@B26]\]. Unlike the expressed *vlp1*~*B.\ recurrentis\ A1*~ where there is a nearly perfect UP element consensus sequence there exists a long polydT tract. Silencing of the archived variant protein gene copies in *B. hermsii* is due to the absence of a promoter upstream of these genes \[[@B6]\], whereas in *B. turicatae* some silent variant protein genes lack promoter features while others lack both a promoter signature and an initiation codon \[[@B22]\]. Unexpectedly, we find that the silent copy of *vlp1*~*B.\ recurrentis\ A1*~ contains all the features necessary for expression. Although the upstream sequences of silent and expressed *vlp1*~*B.\ recurrentis\ A1*~ are dissimilar, both copies have a consensus lipoprotein leader sequence and putative characteristic features of a constitutive promoter. These observations are based on the assumption that promoters in *B. recurrentis* are similar to those in *Escherichia coli*. However, only mRNA corresponding to the expressed copy could be detected in isolate A1. It is possible that the promoter present in the silent copy is not recognised as functional. An alternative interpretation is that in *B. recurrentis* transcription of the silent copy of the *vlp1*~*B.\ recurrentis\ A1*~ gene is actively repressed. Such a silencing mechanism to prevent inappropriate expression of a variant protein gene has not been reported previously for Borreliae \[[@B6],[@B27],[@B28]\] and may be unique to *B. recurrentis*. Active repression of surface antigen gene expression has been described in trypanosomes and is achieved by telomere silencing \[[@B29]\] and further investigation is required to determine whether a similar process operates here. In that context, it would be interesting to pinpoint the location of the silent *vlp1*~*B.\ recurrentis\ A1*~ gene relative to plasmid ends.

Conclusions
===========

The clinical isolate of *B. recurrentis*, A1, was demonstrated to contain two copies of a *vlp1* gene on plasmids of 54 and 24 kbp. In a further isolate, A17, not expressing this gene, the *vlp1* gene was only present on a 54 kbp plasmid. Northern blotting confirmed the expression site was located on the 24 kbp plasmid. The cloning and sequencing of the *vlp1*~*B.\ recurrentis\ A1*~ loci have highlighted the broad similarities in the organisation of variant protein genes in relapsing fever Borreliae. However this work has also uncovered some putative features that may be unique to *B. recurrentis* and that warrant future studies. Unlike other relapsing fever *Borrelia* studied to date, the upstream sequences of both silent and expressed genes contain features necessary for expression, suggesting the possibility of control of transcription through a silencing mechanism.
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